Equine Pituitary Pars Intermedia Dysfunction (PPID) previously known as Equine Cushing’s disease can often go undiagnosed. It was previously thought to be a disease of older horses but more and more horses are being diagnosed at an earlier age1. Because the early signs of the disease can often be very subtle, it may often be overlooked until the disease is in an advanced stage. If PPID is left untreated it can lead to a variety of problems for horses ranging from abnormal fat deposits to the devastating consequences from laminitis2.
To raise recognition of PPID, Boehringer Ingelheim is sponsoring a PPID awareness campaign through the ‘talkaboutlaminitis’ initiative. For a limited time Boehringer Ingelheim, in conjunction with IDEXX is providing free ACTH testing for equine vets that suspect they have a patient with PPID. By going onto www.talkaboutlaminitis.com.au you can access the free ACTH testing vouchers today.
Prascend® is the optimal solution for the management of PPID. With a 2 year shelf life Prascend’s® tableted design ensures that a stable quality formulation of pergolide is being delivered with each dose. By using Prascend® as part of your PPID management protocol, you can help reduce the signs of PPID and improve horses quality of life3.
For more information, go to
Donaldson MT, McDonnell SM, Schanbacher BJ, Lamb SV, McFarlane D, Beech J. Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses. J Vet Intern Med. 2005;19(2):217-222.
McGowan TW, Hodgson DR, McGowan CM. The prevalence of equine Cushing’s syndrome in aged horses. In: Proceedings from the 25th American College of Veterinary Internal Medicine Forum; June 6-9, 2007; Seattle, WA. Abstract 603.
PRASCEND® (pergolide mesylate) [Freedom of Information Summary]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2011.